Denali Therapeutics Statistics
Total Valuation
DNLI has a market cap or net worth of $2.28 billion. The enterprise value is $1.35 billion.
Important Dates
The last earnings date was Monday, August 11, 2025, before market open.
Earnings Date | Aug 11, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
DNLI has 146.42 million shares outstanding. The number of shares has increased by 14.84% in one year.
Current Share Class | 146.42M |
Shares Outstanding | 146.42M |
Shares Change (YoY) | +14.84% |
Shares Change (QoQ) | +0.13% |
Owned by Insiders (%) | 4.88% |
Owned by Institutions (%) | 94.48% |
Float | 132.11M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | 106.02 |
PB Ratio | 2.20 |
P/TBV Ratio | 2.22 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.27, with a Debt / Equity ratio of 0.05.
Current Ratio | 10.27 |
Quick Ratio | 9.89 |
Debt / Equity | 0.05 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -313.87 |
Financial Efficiency
Return on equity (ROE) is -39.69% and return on invested capital (ROIC) is -26.56%.
Return on Equity (ROE) | -39.69% |
Return on Assets (ROA) | -24.99% |
Return on Invested Capital (ROIC) | -26.56% |
Return on Capital Employed (ROCE) | -49.63% |
Revenue Per Employee | n/a |
Profits Per Employee | -$1.14M |
Employee Count | 422 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, DNLI has paid $68,000 in taxes.
Income Tax | 68,000 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -37.14% in the last 52 weeks. The beta is 1.36, so DNLI's price volatility has been higher than the market average.
Beta (5Y) | 1.36 |
52-Week Price Change | -37.14% |
50-Day Moving Average | 14.33 |
200-Day Moving Average | 17.71 |
Relative Strength Index (RSI) | 61.87 |
Average Volume (20 Days) | 1,817,725 |
Short Selling Information
The latest short interest is 12.83 million, so 8.76% of the outstanding shares have been sold short.
Short Interest | 12.83M |
Short Previous Month | 12.68M |
Short % of Shares Out | 8.76% |
Short % of Float | 9.71% |
Short Ratio (days to cover) | 8.70 |
Income Statement
Revenue | n/a |
Gross Profit | -396.06M |
Operating Income | -533.58M |
Pretax Income | -419.62M |
Net Income | -479.03M |
EBITDA | -529.42M |
EBIT | -533.58M |
Earnings Per Share (EPS) | -$2.81 |
Full Income Statement Balance Sheet
The company has $898.95 million in cash and $47.97 million in debt, giving a net cash position of $929.44 million or $6.35 per share.
Cash & Cash Equivalents | 898.95M |
Total Debt | 47.97M |
Net Cash | 929.44M |
Net Cash Per Share | $6.35 |
Equity (Book Value) | 1.03B |
Book Value Per Share | 7.05 |
Working Capital | 843.65M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$349.62 million and capital expenditures -$18.33 million, giving a free cash flow of -$367.95 million.
Operating Cash Flow | -349.62M |
Capital Expenditures | -18.33M |
Free Cash Flow | -367.95M |
FCF Per Share | -$2.51 |
Full Cash Flow Statement Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
DNLI does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -14.84% |
Shareholder Yield | -14.84% |
Earnings Yield | -21.01% |
FCF Yield | -16.14% |
Dividend Details Analyst Forecast
The average price target for DNLI is $33.62, which is 115.93% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $33.62 |
Price Target Difference | 115.93% |
Analyst Consensus | Strong Buy |
Analyst Count | 15 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | -32.47% |
Stock Forecasts Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |